1-48. (Canceled)

49. (Currently Amended) A method for treating ~~or preventing~~ a disease characterized by beta-amyloid deposits in the brain comprising administering to a patient an effective therapeutic amount of a hydroxyethylene compound of the formula



(XII)

where R_1 is:

(I) C_1-C_6 alkyl, unsubstituted or substituted with one, two or three C_1-C_3 alkyl, -F, -Cl, -Br, -I, -OH, -NH_2, -C≡N, -CF_3, or -N_3,

(II) -$(CH_2)_{1-2}$-S-CH_3,

(III) -CH_2-CH_2-S-CH_3,

(IV) -CH_2-(C_2-C_6 alkenyl) unsubstituted or substituted by one -F,

(V) -$(CH_2)_{0-3}$-($R_{1\text{-aryl}}$) where $R_{1\text{-aryl}}$ is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl unsubstituted or substituted on the aryl ring with one or two of the following substituents which can be the same or different:

(A) C_1-C_3 alkyl,

(B) -CF_3,

(C) -F, Cl, -Br and -I,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(D) C_1-C_3 alkoxy,

(E) $-O-CF_3$,

(F) $-NH_2$,

(G) -OH, or

(H) $-C\equiv N$,

(VI) $-(CH_2)_{n1}-(R_{1\text{-heteroaryl}})$ where n_1 is 0, 1, 2, or 3 and $R_{1\text{-heteroaryl}}$ is:

(A) pyridinyl,

(B) pyrimidinyl,

(C) quinolinyl,

(D) indenyl,

(E) indanyl,

(F) benzothiophenyl,

(G) indolyl,

(H) indolinyl,

(I) pyridazinyl,

(J) pyrazinyl,

(K) isoindolyl,

(L) isoquinolyl,

(M) quinazolinyl,

(N) quinoxalinyl,

(O) phthalazinyl,

(P) imidazolyl,

(Q) isoxazolyl,

(R) pyrazolyl,

(S) oxazolyl,

(T) thiazolyl,

(U) indolizinyl,

(V) indazolyl,

(W) benzothiazolyl,

(X) benzimidazolyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(Y) benzofuranyl,

(Z) furanyl,

(AA) thienyl,

(BB) pyrrolyl,

(CC) oxadiazolyl,

(DD) thiadiazolyl,

(EE) triazolyl,

(FF) tetrazolyl,

(GG) 1, 4-benzodioxan

(HH) purinyl,

(II) oxazolopyridinyl,

(JJ) imidazopyridinyl,

(KK) isothiazolyl,

(LL) naphthyridinyl,

(MM) cinnolinyl,

(NN) carbazolyl,

(OO) β-carbolinyl,

(PP) isochromanyl,

(QQ) chromanyl,

(RR) furazanyl,

(SS) tetrahydroisoquinoline,

(TT) isoindolinyl,

(UU) isobenzotetrahydrofuranyl,

(VV) isobenzotetrahydrothienyl,

(WW) isobenzothiophenyl,

(XX) benzoxazolyl, or

(YY) pyridopyridinyl,

where the $R_{1\text{-heteroaryl}}$ group is bonded to $-(CH_2)_{0-3}-$ by any ring atom of the parent $R_{N\text{-heteroaryl}}$ group substituted by hydrogen such that the new bond to the $R_{1\text{-heteroaryl}}$ group replaces the hydrogen atom

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

and its bond, where heteroaryl is unsubstituted or substituted with one or two:

(1) C_1-C_3 alkyl,

(2) $-CF_3$,

(3) -F, Cl, -Br, or -I,

(4) C_1-C_3 alkoxy,

(5) $-O-CF_3$,

(6) $-NH_2$,

(7) -OH, or

(8) $-C\equiv N$,

with the proviso that when n_1 is zero $R_{1\text{-heteroaryl}}$ is not bonded to the carbon chain by nitrogen, or

(VII) $-(CH_2)_{n1}-(R_{1-\text{heterocycle}})$ where n_1 is as defined above and

$R_{1-\text{heterocycle}}$ is:

(A) morpholinyl,

(B) thiomorpholinyl,

(C) thiomorpholinyl S-oxide,

(D) thiomorpholinyl S,S-dioxide,

(E) piperazinyl,

(F) homopiperazinyl,

(G) pyrrolidinyl,

(H) pyrrolinyl,

(I) tetrahydropyranyl,

(J) piperidinyl,

(K) tetrahydrofuranyl, or

(L) tetrahydrothiophenyl,

where the $R_{1\text{-heterocycle}}$ group is bonded by any atom of the parent $R_{1\text{-heterocycle}}$ group substituted by hydrogen such that the new bond to the $R_{1\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

two:

(1) =O,

(2) C_1-C_3 alkyl,

(3) $-CF_3$,

(4) -F, Cl, -Br and -I,

(5) C_1-C_3 alkoxy,

(6) $-O-CF_3$,

(7) $-NH_2$,

(8) -OH, or

(9) $-C\equiv N$,

with the proviso that when n_1 is zero $R_{1\text{-heterocycle}}$ is not bonded to the carbon chain by nitrogen;

where R_2 is:

(I) -H,

(II) C_1-C_6 alkyl, or

(III) $-(CH_2)_{0-4}-R_{2-1}$ where R_{2-1} is (C_3-C_6)cycloalkyl, $R_{1\text{-aryl}}$ or $R_{1\text{-heteroaryl}}$ where $R_{1\text{-aryl}}$ and $R_{1\text{-heteroaryl}}$ are as defined above,

where R_N is:

(I) $R_{N-1}-X_N-$ where X_N is:

(A) -CO-,

(B) $-SO_2-$,

(C) $-(CR'R'')_{1-6}$ where R′ and R″ are the same or different and are -H or C_1-C_4 alkyl,

(D) $-CO-(CR'R'')_{1-6}-X_{N-1}$ where X_{N-1} is -O-, -S- and -NR′R"- and where R′ and R″ are as defined above,

(E) a single bond;

where R_{N-1} is:

(A) $R_{N\text{-aryl}}$ where $R_{N\text{-aryl}}$ is phenyl, 1-naphthyl and 2-naphthyl unsubstituted or substituted with

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

one, two, three or four of the following substituents which can be the same or different and are:

(1) C_1-C_6 alkyl,

(2) -F, -Cl, -Br, or -I,

(3) -OH,

(4) $-NO_2$,

(5) -CO-OH,

(6) $-C\equiv N$,

(7) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are:

(a) -H,

(b) -C_1-C_6 alkyl unsubstituted or substituted with one

(i) -OH, or

(ii) $-NH_2$,

(c) -C_1-C_6 alkyl unsubstituted or substituted with one to three -F, -Cl, -Br, or -I,

(d) -C_3-C_7 cycloalkyl,

(e) -(C_1-C_2 alkyl)-(C_3-C_7 cycloalkyl),

(f) -(C_1-C_6 alkyl)-O-(C_1-C_3 alkyl),

(g) -C_1-C_6 alkenyl with one or two double bonds,

(h) -C_1-C_6 alkynyl with one or two triple bonds,

(i) -C_1-C_6 alkyl chain with one double bond and one triple bond,

(j) $-R_{1\text{-aryl}}$ where $R_{1\text{-aryl}}$ is as defined above, or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(k) $-R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(8) $-CO-(C_3-C_{12}$ alkyl),

(9) $-CO-(C_3-C_6$ cycloalkyl),

(10) $-CO-R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(11) $-CO-R_{1\text{-heterocycle}}$ where $R_{1\text{-heterocycle}}$ is as defined above,

(12) $-CO-R_{N-4}$ where R_{N-4} is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1-C_3 alkyl,

(13) $-CO-O-R_{N-5}$ where R_{N-5} is:

(a) C_1-C_6 alkyl, or

(b) $-(CH_2)_{0-2}-(R_{1\text{-aryl}})$ where $R_{1\text{-aryl}}$ is as defined above,

(14) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(15) $-SO-(C_1-C_8$ alkyl),

(16) $-SO_2-(C_3-C_{12}$ alkyl),

(17) $-NH-CO-O-R_{N-5}$ where R_{N-5} is as defined above,

(18) $-NH-CO-N(C_1-C_3$ alkyl$)_2$,

(19) $-N-CS-N(C_1-C_3$ alkyl$)_2$,

(20) $-N(C_1-C_3$ alkyl$)-CO-R_{N-5}$ where R_{N-5} is as defined above,

(21) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,

(22) $-R_{N-4}$ where R_{N-4} is as defined above,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(23) -O-CO-(C_1-C_6 alkyl),

(24) -O-CO-N(C_1-C_3 alkyl)$_2$,

(25) -O-CS-N(C_1-C_3 alkyl)$_2$,

(26) -O-(C_1-C_6 alkyl),

(27) -O-(C_2-C_5 alkyl)-COOH,

(28) -S-(C_1-C_6 alkyl),

(29) C_1-C_6 alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F,

(30) -O-(C_1-C_6 alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F, or

(31) -O-ϕ,

(B) $-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is:

(A) pyridinyl,

(B) pyrimidinyl,

(C) quinolinyl,

(D) indenyl,

(E) indanyl,

(F) benzothiophenyl,

(G) indolyl,

(H) indolinyl,

(I) pyridazinyl,

(J) pyrazinyl,

(K) isoindolyl,

(L) isoquinolyl,

(M) quinazolinyl,

(N) quinoxalinyl,

(O) phthalazinyl,

(P) imidazolyl,

(Q) isoxazolyl,

(R) pyrazolyl,

(S) oxazolyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(T) thiazolyl,

(U) indolizinyl,

(V) indazolyl,

(W) benzothiazolyl,

(X) benzimidazolyl,

(Y) benzofuranyl,

(Z) furanyl,

(AA) thienyl,

(BB) pyrrolyl,

(CC) oxadiazolyl,

(DD) thiadiazolyl,

(EE) triazolyl,

(FF) tetrazolyl,

(GG) 1, 4-benzodioxan

(HH) purinyl,

(II) oxazolopyridinyl,

(JJ) imidazopyridinyl,

(KK) isothiazolyl,

(LL) naphthyridinyl,

(MM) cinnolinyl,

(NN) carbazolyl,

(OO) β-carbolinyl,

(PP) isochromanyl,

(QQ) chromanyl,

(RR) furazanyl,

(SS) tetrahydroisoquinoline,

(TT) isoindolinyl,

(UU) isobenzotetrahydrofuranyl,

(VV) isobenzotetrahydrothienyl,

(WW) isobenzothiophenyl,

(XX) benzoxazolyl, or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(YY) pyridopyridinyl,

where the $R_{N\text{-heteroaryl}}$ group is bonded by any atom of the parent $R_{N\text{-heteroaryl}}$ group substituted by hydrogen such that the new bond to the $R_{N\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heteroaryl is unsubstituted or substituted with one or two:

(1) C_1-C_6 alkyl,

(2) -F, -Cl, -Br, or - I,

(3) -OH,

(4) $-NO_2$,

(5) -CO-OH,

(6) -C≡N,

(7) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are:

(a) -H,

(b) -C_1-C_6 alkyl unsubstituted or substituted with one

(i) -OH, or

(ii) $-NH_2$,

(c) -C_1-C_6 alkyl unsubstituted or substituted with 1, 2, or 3 -F, -Cl, -Br, or -I,

(d) -C_3-C_7 cycloalkyl,

(e -(C_1-C_2 alkyl)-(C_3-C_7 cycloalkyl),

(f) -(C_1-C_6 alkyl)-O-(C_1-C_3 alkyl),

(g) -C_1-C_6 alkenyl with one or two double bonds,

(h) -C_1-C_6 alkynyl with one or two triple bonds,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(i) -C_1-C_6 alkyl chain with one double bond and one triple bond,

(j) -$R_{1\text{-aryl}}$ where $R_{1\text{-aryl}}$ is as defined above, or

(k) -$R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(8) -CO-(C_3-C_{12} alkyl),

(9) -CO-(C_3-C_6 cycloalkyl),

(10) -CO-$R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(11) -CO-$R_{1\text{-heterocycle}}$ where $R_{1\text{-heterocycle}}$ is as defined above,

(12) -CO-$R_{N\text{-}4}$ where $R_{N\text{-}4}$ is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1-C_3 alkyl,

(13) -CO-O-$R_{N\text{-}5}$ where $R_{N\text{-}5}$ is:

(a) C_1-C_6 alkyl, or

(b) -$(CH_2)_{0\text{-}2}$-($R_{1\text{-aryl}}$) where $R_{1\text{-aryl}}$ is as defined above,

(14) -SO_2-$NR_{N\text{-}2}R_{N\text{-}3}$ where $R_{N\text{-}2}$ and $R_{N\text{-}3}$ are as defined above,

(15) -SO-(C_1-C_8 alkyl),

(16) -SO_2-(C_3-C_{12} alkyl),

(17) -NH-CO-O-$R_{N\text{-}5}$ where $R_{N\text{-}5}$ is as defined above,

(18) -NH-CO-N(C_1-C_3 alkyl)$_2$,

(19) -N-CS-N(C_1-C_3 alkyl)$_2$,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(20) $-N(C_1-C_3\ alkyl)-CO-R_{N-5}$ where R_{N-5} is as defined above,

(21) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,

(22) $-R_{N-4}$ where R_{N-4} is as defined above,

(23) $-O-CO-(C_1-C_6\ alkyl)$,

(24) $-O-CO-N(C_1-C_3\ alkyl)_2$,

(25) $-O-CS-N(C_1-C_3\ alkyl)_2$,

(26) $-O-(C_1-C_6\ alkyl)$,

(27) $-O-(C_2-C_5\ alkyl)-COOH$, or

(28) $-S-(C_1-C_6\ alkyl)$,

(C) $-R_{N-aryl}-R_{N-aryl}$ where $-R_{N-aryl}$ is as defined above,

(D) $-R_{N-aryl}-R_{N-heteroaryl}$ where $-R_{N-aryl}$ and $-R_{N-heteroaryl}$ are as defined above,

(E) $-R_{N-heteroaryl}-R_{N-aryl}$ where $-R_{N-aryl}$ and $-R_{N-heteroaryl}$ are as defined above,

(F) $-R_{N-heteroaryl}-R_{N-heteroaryl}$ where $R_{N-heteroaryl}$ is as defined above,

(G) $-R_{N-aryl}-O-R_{N-aryl}$ where $-R_{N-aryl}$ is as defined above,

(H) $-R_{N-aryl}-S-R_{N-aryl}$ where $-R_{N-aryl}$ is as defined above,

(I) $-R_{N-heteroaryl}-O-R_{N-heteroaryl}$ where $R_{N-heteroaryl}$ is as defined above,

(J) $-R_{N-heteroaryl}-S-R_{N-heteroaryl}$ where $R_{N-heteroaryl}$ is as defined above,

(K) $-R_{N-aryl}-CO-R_{N-aryl}$ where $-R_{N-aryl}$ is as defined above,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(L) $-R_{N\text{-}aryl}-CO-R_{N\text{-}heteroaryl}$ where $-R_{N\text{-}aryl}$ and $R_{N\text{-}heteroaryl}$ are as defined above,

(M) $-R_{N\text{-}aryl}-SO_2-R_{N\text{-}aryl}$ where $-R_{N\text{-}aryl}$ is as defined above,

(N) $-R_{N\text{-}heteroaryl}-CO-R_{N\text{-}heteroaryl}$ where $R_{N\text{-}heteroaryl}$ is as defined above,

(O) $-R_{N\text{-}heteroaryl}-SO_2-R_{N\text{-}heteroaryl}$ where $R_{N\text{-}heteroaryl}$ is as defined above,

(P) $-R_{N\text{-}aryl}-O-(C_1-C_8\ alkyl)-\phi$ where $R_{N\text{-}aryl}$ is as defined above,

(Q) $-R_{N\text{-}aryl}-S-(C_1-C_8\ alkyl)-\phi$ where $R_{N\text{-}aryl}$ is as defined above,

(R) $-R_{N\text{-}heteroaryl}-O-(C_1-C_8\ alkyl)-\phi$ where $R_{N\text{-}heteroaryl}$ is as defined above, or

(S) $-R_{N\text{-}heteroaryl}-S-(C_1-C_8\ alkyl)-\phi$ where $R_{N\text{-}heteroaryl}$ is as defined above,

(II) $A-X_N-$ where X_N is $-CO-$,

wherein A is

(A) $-T-E-(Q)_{m'}$,

(1) where -T is



where

(a) x =1 when y = 1 and x = 2 when y = 0,

(b) m is 0, 1, 2 or 3,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(c) the values of x and y vary independently on each carbon when m is 2 and 3, and

(d) R''' varies independently on each carbon and is H, (C_1-C_2) alkyl, phenyl, or phenyl(C_1-C_3)alkyl;

(2) -E is

(a) C_1-C_5 alkyl, but only if m' does not equal 0,

(b) methylthioxy(C_2-C_4)alkyl,

(c) an aryl group having 5 to 7 atoms when monocyclic or having 8 to 12 atoms when fused,

(d) a heterocyclic group having 5 to 7 atoms when monocyclic or having 8 to 12 atoms when fused,

(e) a mono or fused ring cycloalkyl group having 5 to 10 carbon atoms,

(f) biphenyl,

(g) diphenyl ether,

(h) diphenylketone,

(i) phenyl(C_1-C_8)alkyloxyphenyl, or

(j) C_1-C_6 alkoxy;

(3) -Q is

(a) C_1-C_3 alkyl,

(b) C_1-C_3 alkoxy,

(c) C_1-C_3 alkylthioxy,

(d) C_1-C_6 alkylacylamino,

(e) C_1-C_6 alkylacyloxy,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(f) amido (including primary, C_1-C_6 alkyl and phenyl secondary and tertiary amino moieties),

(g) C_1-C_6 alkylamino

(h) phenylamino,

(i) carbamyl (including C_1-C_6 alkyl and phenyl amides and esters),

(j) carboxyl (including C_1-C_6 alkyl and phenyl esters),

(k) carboxy(C_2-C_5)alkoxy,

(l) carboxy(C_2-C5)alkylthioxy,

(m) heterocyclylacyl,

(n) heteroarylacyl, or

(o) hydroxyl;

(4) m' is 0, 1, 2 or 3;

(B) $-E(Q)_{m'}$, wherein E and -Q are as defined as above and m" is 0, 1, 2, or 3;

(C) -T-E wherein -E and -Q are as defined as above; or

(D) -E wherein -E is as defined as above;

(III) -CO-(C_1-C_6 alkyl) where alkyl is unsubstituted or substituted with one or two:

(A) -OH,

(B) -C_1-C_6 alkoxy,

(C) -C_1-C_6 thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is -H, C_1-C_6 alkyl or -ϕ,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) -SO_2-(C_1-C_8 alkyl),

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl),

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl),

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} is the same or different and are as defined above, or

(O) $-O-(C_1-C_5$ alkyl)$-COOH$,

(IV) $-CO-(C_1-C_3$ alkyl$)-O-(C_1-C_3$ alkyl) where alkyl is unsubstituted or substituted with one or two

(A) $-OH$,

(B) $-C_1-C_6$ alkoxy,

(C) $-C_1-C_6$ thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is $-H$, C_1-C_6 alkyl or $-\phi$,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) $-SO_2-(C_1-C_8$ alkyl),

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl),

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl),

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} are the same or different and are as defined above, or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(O) -O-(C_1-C_5 alkyl)-COOH,

(V) -CO-(C_1-C_3 alkyl)-S-(C_1-C_3 alkyl) where alkyl is unsubstituted or substituted with one or two

(A) -OH,

(B) -C_1-C_6 alkoxy,

(C) -C_1-C_6 thioalkoxy,

(D) -CO-O-R_{N-8} where R_{N-8} is -H, C_1-C_6 alkyl or -ϕ,

(E) -CO-$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) -CO-R_{N-4} where R_{N-4} is as defined above,

(G) -SO_2-(C_1-C_8 alkyl),

(H) -SO_2-$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) -NH-CO-(C_1-C_6 alkyl),

(J) -NH-CO-O-R_{N-8} where R_{N-8} is as defined above,

(K) -$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) -R_{N-4} where R_{N-4} is as defined above,

(M) -O-CO-(C_1-C_6 alkyl),

(N) -O-CO-$NR_{N-8}R_{N-8}$ where the R_{N-8} are the same or different and are as defined above, or

(O) -O-(C_1-C_5 alkyl)-COOH,

(VI) -CO-CH(-$(CH_2)_{0-2}$-O-R_{N-10})-$(CH_2)_{0-2}$-$R_{N\text{-}aryl}$/$R_{N\text{-}heteroaryl}$) where R_{N-aryl} and $R_{N-heteroaryl}$ are as defined above, where R_{N-10} is:

(A) -H,

(B) C_1-C_6 alkyl,

(C) C_3-C_7 cycloalkyl,

(D) C_2-C_6 alkenyl with one double bond,

(E) C_2-C_6 alkynyl with one triple bond,

(F) R_{1-aryl} where R_{1-aryl} is as defined above, or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(G) $R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above;

where B is -O-, -NH-, or -N(C_1-C_6 alkyl)-;

where R_C is:

~~(I) -(C_1-C_{10})alkyl-K_{1-3} in which:~~

~~(A) the alkyl chain is unsubstituted or substituted with one -OH,~~

~~(B) the alkyl chain is unsubstituted or substituted with one C_1-C_6 alkoxy unsubstituted or substituted with 1-5 -F,~~

~~(C) the alkyl chain is unsubstituted or substituted with one -O-ϕ,~~

~~(D) the alkyl chain is unsubstituted or substituted with 1-5 -F,~~

~~(E) the alkyl chain is unsubstituted or substituted with a combination of up to three atoms of oxygen and sulfur each such atom replacing one carbon,~~

~~(F) each K is:~~

~~(1) H,~~

~~(2) C_1-C_3 alkyl,~~

~~(3) C_1-C_3 alkoxy,~~

~~(4) C_1-C_3 alkylthioxy,~~

~~(5) C_1-C_6 alkylacylamino,~~

~~(6) C_1-C_6 alkylacyloxy,~~

~~(7) amido~~

~~(8) C_1-C_6 alkylamino~~

~~(9) phenylamino,~~

~~(10) carbamyl~~

~~(11) carboxyl~~

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

~~(12) carboxy(C_2-C_5)alkoxy,~~

~~(13) carboxy(C_2-C5)alkylthioxy,~~

~~(14) heterocyclylacyl,~~

~~(15) heteroarylacyl,~~

~~(16) amino unsubstituted or substituted with C_1-C_6 alkyl,~~

~~(17) hydroxyl, or~~

~~(18) carboxyl methyl ester;~~

~~(II) -$(CH_2)_{0-3}$-J-[(-$(CH_2)_{0-3}$-K]$_{1-3}$ where K is as defined above and J is:~~

~~(A) a 5 to 7 atom monocyclic aryl group,~~

~~(B) a 8 to 12 atom multicyclic aryl group,~~

~~(C) a 5 to 7 atom heterocyclic group,~~

~~(D) a 8 to 12 atom multicyclic heterocyclic group, or~~

~~(E) a 5 to 10 atom monocyclic or multicyclic cycloalkyl group;~~

~~(III)~~ -$(CH_2)_{0-3}$-(C_3-C_7) cycloalkyl where cycloalkyl can be unsubstituted or substituted with one, two or three

(A) C_1-C_3 alkyl unsubstituted or substituted with 1, 2, 3, or 4 -F,

-Cl, -Br, or -I,

(B) -CO-OH,

(C) -CO-O-(C_1-C_4 alkyl),

(D) -OH, or

(E) C_1-C_6 alkoxy,

~~(IV) -$(CH_2)_{2-6}$-OH,~~

~~(V) -$(CR_{C-x}R_{C-y})_{0-4}$-R_{C-aryl} where R_{C-x} and R_{C-y} are -H, C_1-C_4 alkyl and ϕ- and R_{C-aryl} is the same as R_{N-aryl},~~

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

~~(VI) $-(CH_2)_{0-4}-R_{C\text{-}heteroaryl}$ where $R_{C\text{-}heteroaryl}$ is:~~

~~(A) pyridinyl,~~

~~(B) pyrimidinyl,~~

~~(C) quinolinyl,~~

~~(D) indenyl,~~

~~(E) indanyl,~~

~~(F) benzothiophenyl,~~

~~(G) indolyl,~~

~~(H) indolinyl,~~

~~(I) pyridazinyl,~~

~~(J) pyrazinyl,~~

~~(K) isoindolyl,~~

~~(L) isoquinolyl,~~

~~(M) quinazolinyl,~~

~~(N) quinoxalinyl,~~

~~(O) phthalazinyl,~~

~~(P) isoxazolyl,~~

~~(Q) pyrazolyl,~~

~~(R) indolizinyl,~~

~~(S) indazolyl,~~

~~(T) benzothiazolyl,~~

~~(U) benzimidazolyl,~~

~~(V) benzofuranyl,~~

~~(W) furanyl,~~

~~(X) thienyl,~~

~~(Y) pyrrolyl,~~

~~(Z) oxadiazolyl,~~

~~(AA) thiadiazolyl,~~

~~(BB) triazolyl,~~

~~(CC) tetrazolyl,~~

~~(DD) 1, 4-benzodioxan~~

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(EE) purinyl,

(FF) oxazolopyridinyl,

(GG) imidazopyridinyl,

(HH) isothiazolyl,

(II) naphthyridinyl,

(JJ) cinnolinyl,

(KK) carbazolyl,

(LL) β-carbolinyl,

(MM) isochromanyl,

(NN) chromanyl,

(OO) furazanyl,

(PP) tetrahydroisoquinoline,

(QQ) isoindolinyl,

(RR) isobenzotetrahydrofuranyl,

(SS) isobenzotetrahydrothienyl,

(TT) isobenzothiophenyl,

(UU) benzoxazolyl, or

(VV) pyridopyridinyl,

(VII) $-(CH_2)_{0-4}-R_{C\text{-}heterocycle}$ where $R_{C\text{-}heterocycle}$ is the same as $R_{1\text{-}heterocycle}$,

(VIII) $-C(R_{C\text{-}1})(R_{C\text{-}2})-CO-NH-R_{C\text{-}3}$ where $R_{C\text{-}1}$ and $R_{C\text{-}2}$ are the same or different and are:

(A) -H,

(B) $-C_1-C_6$ alkyl,

(C) $-(C_1-C_4$ alkyl$)-R_{C'\text{-}aryl}$ where $R_{C'\text{-}aryl}$ is as defined above for $R_{1\text{-}aryl}$,

(D) $-(C_1-C_4$ alkyl$)-R_{C\text{-}heteroaryl}$ where $R_{C\text{-}heteroaryl}$ is as defined above,

(E) $-(C_1-C_4$ alkyl$)-R_{C\text{-}heterocycle}$ where $R_{C\text{-}heterocycle}$ is as defined above,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(F) $-R_{C\text{-heteroaryl}}$ where $R_{C\text{-heteroaryl}}$ is as defined above,

(G) $-R_{C\text{-heterocycle}}$ where $R_{C\text{-heterocycle}}$ is as defined above,

(H) $-(CH_2)_{1-4}-OH$,

(I) $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{1-4}-R_{C'\text{-aryl}}$ where R_{C-4} is -O-, -S-, -NH- or

$-NHR_{C-5}$- where R_{C-5} is C_1-C_6 alkyl, and where $R_{C'\text{-aryl}}$ is as defined above,

(J) $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{1-4}-R_{C\text{-heteroaryl}}$ where R_{C-4} and $R_{C\text{-heteroaryl}}$ are as defined above, or

(K) $-R_{C'\text{-aryl}}$ where $R_{C'\text{-aryl}}$ is as defined above,

and where R_{C-3} is:

(A) -H,

(B) $-C_1$-C_6 alkyl,

(C) $-R_{C'\text{-aryl}}$ where $R_{C'\text{-aryl}}$ is as defined above,

(D) $-R_{C\text{-heteroaryl}}$ where $R_{C\text{-heteroaryl}}$ is as defined above,

(E) $-R_{C\text{-heterocycle}}$ where $R_{C\text{-heterocycle}}$ is as defined above,

(F) $-(C_1$-C_4 alkyl)$-R_{C'\text{-aryl}}$ where $R_{C'\text{-aryl}}$ is as defined above,

(G) $-(C_1$-C_4 alkyl)$-R_{C\text{-heteroaryl}}$ where $R_{C\text{-heteroaryl}}$ is as defined above, or

(H) $-(C_1$-C_4 alkyl)$-R_{C\text{-heterocycle}}$ where $R_{C\text{-heterocycle}}$ is as defined above,

(IX) $-CH(\phi)_2$,

(X) -cyclopentyl or -cyclohexyl ring fused to a phenyl or heteroaryl ring where heteroaryl is as defined above and phenyl and heteroaryl are unsubstituted or substituted with one, two or three:

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

~~(A) C_1-C_3-alkyl,~~

~~(B) $-CF_3$,~~

~~(C) -F, -Cl, -Br and -I,~~

~~(D) C_1-C_3-alkoxy,~~

~~(E) $-OCF_3$,~~

~~(F) $-NH_2$,~~

~~(G) -OH, or~~

~~(H) $-C\equiv N$,~~

~~(XI) $-CH_2-C\equiv CH$;~~

~~(XII) $-(CH_2)_{0-1}-CHR_{C-5}-(CH_2)_{0-1}-\phi$ where R_{C-5} is:~~

~~(A) -OH, or~~

~~(B) $-CH_2-OH$;~~

~~(XIII) $-CH(-\phi)-CO-O(C_1-C_3\text{-alkyl})$;~~

~~(XIV) $-CH(-CH_2-OH)-CH(-OH)-\phi-NO_2$;~~

~~(XV) $-(CH_2)_2-O-(CH_2)_2-OH$;~~

~~(XVI) $-CH_2-NH-CH_2-CH(-O-CH_2-CH_3)_2$;~~

~~(XVII) $-(C_2-C_8)$ alkynyl; or~~

~~(XVIII) -H;~~ or a pharmaceutically acceptable salt thereof.

50. (Original) The method of claim 49, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 0.1nM to about 200μM.

51. (Original) The method of claim 50, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 10nM to about 100μM.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

52. (Original) The method of claim 51, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 100nM to about 50μM.

53. (Original) The method of claim 52, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 1μM to about 10μM.

54. (Currently Amended) The method of claim 49, wherein said ~~thereapeutic~~ therapeutic amount is in the range of from about 0.1 to about 1000 mg/day.

55. (Currently Amended) The method of claim 49, wherein said ~~thereapeutic~~ therapeutic amount is in the range of from about 15 to about 1500 mg/day.

56. (Currently Amended) The method of claim 55, wherein said ~~thereapeutic~~ therapeutic amount is in the range of from about 1 to about 100 mg/day.

57. (Currently Amended) The method of claim 56, wherein said ~~thereapeutic~~ therapeutic amount is in the range of from about 5 to about 50 mg/day.

58. (Original) The method of claim 49, wherein said disease is Alzheimer's disease.

59. (Currently Amended) The method of claim 49, wherein said disease is Mild Cognitive Impairment, Down's Syndrome, or Hereditary Cerebral ~~Hemmorrhage~~ Hemorrhage with Amyloidosis of the Dutch Type.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

60-98. (Canceled)

99. (New) A method according to claim 49, wherein the compound is

N-[(1*S*, 2*S*, 4*R*)-1-(3,5-Difluorobenzyl)-4-(*syn*, *syn*)-(3,5 dimethoxycyclohexylcarbamoyl)-2-hydroxyhexyl]-*N*,*N*-dipropylisophathalamide;

N-[4-(*R*)-(Cyclohexylmethyl-carbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide;

4-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid methyl ester;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-2-(*R*)-methyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-2-(*R*)-propyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxyl-2-(*R*)-isobutyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([2-(*R*)-Benzyl-6-(3,5-difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-5-methyl-benzoylamino)-2-(*R*)-ethyl-4-(S)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-5-methyl-benzoylamino)-2-(*R*)-ethyl-4-(S)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid methyl ester;

4-(*anti*)-{[6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoylbenzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxyhexanoylamino]-methyl}cyclohexanecarboxylic acid;

N-[(1*S*, 2*S*, 4*R*)-1-(3,5-Difluorobenzyl)-4-(*syn,syn*)-(3,5-dimethoxycyclohexylcarbamoyl)-2-hydroxyhexyl]-*N,N*-dipropylisophathalamide; or

N-[4-(*R*)-(Adamantan-2-ylcarbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-pentyl]-5-methyl-*N,N*-dipropyl-isophthalamide.

100. (New) A method for treating Mild Cognitive Impairment, Down's Syndrome, or Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type comprising administering an effective amount of the formula



(XII)

where R_1 is:

(I) C_1-C_6 alkyl, unsubstituted or substituted with one, two or three C_1-C_3 alkyl, -F, -Cl, -Br, -I, -OH, -NH_2, -C≡N, -CF_3, or -N_3,

(II) -$(CH_2)_{1-2}$-S-CH_3,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(III) $-CH_2-CH_2-S-CH_3$,

(IV) $-CH_2-(C_2-C_6$ alkenyl) unsubstituted or substituted by one -F,

(V) $-(CH_2)_{0-3}-(R_{1\text{-aryl}})$ where $R_{1\text{-aryl}}$ is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl unsubstituted or substituted on the aryl ring with one or two of the following substituents which can be the same or different:

(A) C_1-C_3 alkyl,

(B) $-CF_3$,

(C) -F, Cl, -Br and -I,

(D) C_1-C_3 alkoxy,

(E) $-O-CF_3$,

(F) $-NH_2$,

(G) -OH, or

(H) $-C\equiv N$,

(VI) $-(CH_2)_{n1}-(R_{1\text{-heteroaryl}})$ where n_1 is 0, 1, 2, or 3 and $R_{1\text{-heteroaryl}}$ is:

(A) pyridinyl,

(B) pyrimidinyl,

(C) quinolinyl,

(D) indenyl,

(E) indanyl,

(F) benzothiophenyl,

(G) indolyl,

(H) indolinyl,

(I) pyridazinyl,

(J) pyrazinyl,

(K) isoindolyl,

(L) isoquinolyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(M) quinazolinyl,

(N) quinoxalinyl,

(O) phthalazinyl,

(P) imidazolyl,

(Q) isoxazolyl,

(R) pyrazolyl,

(S) oxazolyl,

(T) thiazolyl,

(U) indolizinyl,

(V) indazolyl,

(W) benzothiazolyl,

(X) benzimidazolyl,

(Y) benzofuranyl,

(Z) furanyl,

(AA) thienyl,

(BB) pyrrolyl,

(CC) oxadiazolyl,

(DD) thiadiazolyl,

(EE) triazolyl,

(FF) tetrazolyl,

(GG) 1, 4-benzodioxan

(HH) purinyl,

(II) oxazolopyridinyl,

(JJ) imidazopyridinyl,

(KK) isothiazolyl,

(LL) naphthyridinyl,

(MM) cinnolinyl,

(NN) carbazolyl,

(OO) β-carbolinyl,

(PP) isochromanyl,

(QQ) chromanyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(RR) furazanyl,

(SS) tetrahydroisoquinoline,

(TT) isoindolinyl,

(UU) isobenzotetrahydrofuranyl,

(VV) isobenzotetrahydrothienyl,

(WW) isobenzothiophenyl,

(XX) benzoxazolyl, or

(YY) pyridopyridinyl,

where the $R_{1\text{-heteroaryl}}$ group is bonded to $-(CH_2)_{0-3}-$ by any ring atom of the parent $R_{N\text{-heteroaryl}}$ group substituted by hydrogen such that the new bond to the $R_{1\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heteroaryl is unsubstituted or substituted with one or two:

(1) C_1-C_3 alkyl,

(2) $-CF_3$,

(3) -F, Cl, -Br, or -I,

(4) C_1-C_3 alkoxy,

(5) $-O-CF_3$,

(6) $-NH_2$,

(7) -OH, or

(8) $-C\equiv N$,

with the proviso that when n_1 is zero $R_{1\text{-heteroaryl}}$ is not bonded to the carbon chain by nitrogen, or

(VII) $-(CH_2)_{n1}-(R_{1-\text{heterocycle}})$ where n_1 is as defined above and

$R_{1-\text{heterocycle}}$ is:

(A) morpholinyl,

(B) thiomorpholinyl,

(C) thiomorpholinyl S-oxide,

(D) thiomorpholinyl S,S-dioxide,

(E) piperazinyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(F) homopiperazinyl,

(G) pyrrolidinyl,

(H) pyrrolinyl,

(I) tetrahydropyranyl,

(J) piperidinyl,

(K) tetrahydrofuranyl, or

(L) tetrahydrothiophenyl,

where the $R_{1\text{-heterocycle}}$ group is bonded by any atom of the parent $R_{1\text{-heterocycle}}$ group substituted by hydrogen such that the new bond to the $R_{1\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or two:

(1) =O,

(2) C_1-C_3 alkyl,

(3) $-CF_3$,

(4) -F, Cl, -Br and -I,

(5) C_1-C_3 alkoxy,

(6) $-O-CF_3$,

(7) $-NH_2$,

(8) -OH, or

(9) $-C\equiv N$,

with the proviso that when n_1 is zero $R_{1\text{-heterocycle}}$ is not bonded to the carbon chain by nitrogen;

where R_2 is:

(I) -H,

(II) C_1-C_6 alkyl, or

(III) $-(CH_2)_{0\text{-}4}-R_{2\text{-}1}$ where $R_{2\text{-}1}$ is $(C_3\text{-}C_6)$cycloalkyl, $R_{1\text{-aryl}}$ or $R_{1\text{-heteroaryl}}$ where $R_{1\text{-aryl}}$ and $R_{1\text{-heteroaryl}}$ are as defined above,

where R_N is:

(I) $R_{N\text{-}1}-X_N-$ where X_N is:

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(A) -CO-,

(B) $-SO_2-$,

(C) $-(CR'R'')_{1-6}$ where R′ and R″ are the same or different and are -H or C_1-C_4 alkyl,

(D) $-CO-(CR'R'')_{1-6}-X_{N-1}$ where X_{N-1} is -O-, -S- and -NR′R"- and where R′ and R″ are as defined above,

(E) a single bond;

where R_{N-1} is:

(A) R_{N-aryl} where R_{N-aryl} is phenyl, 1-naphthyl and 2-naphthyl unsubstituted or substituted with one, two, three or four of the following substituents which can be the same or different and are:

(1) C_1-C_6 alkyl,

(2) -F, -Cl, -Br, or -I,

(3) -OH,

(4) $-NO_2$,

(5) -CO-OH,

(6) -C≡N,

(7) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are:

(a) -H,

(b) $-C_1-C_6$ alkyl unsubstituted or substituted with one

(i) -OH, or

(ii) $-NH_2$,

(c) $-C_1-C_6$ alkyl unsubstituted or substituted with one to three -F, -Cl, -Br, or -I,

(d) $-C_3-C_7$ cycloalkyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(e) $-(C_1-C_2$ alkyl$)-(C_3-C_7$ cycloalkyl),

(f) $-(C_1-C_6$ alkyl$)-O-(C_1-C_3$ alkyl),

(g) $-C_1-C_6$ alkenyl with one or two double bonds,

(h) $-C_1-C_6$ alkynyl with one or two triple bonds,

(i) $-C_1-C_6$ alkyl chain with one double bond and one triple bond,

(j) $-R_{1\text{-aryl}}$ where $R_{1\text{-aryl}}$ is as defined above, or

(k) $-R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(8) $-CO-(C_3-C_{12}$ alkyl),

(9) $-CO-(C_3-C_6$ cycloalkyl),

(10) $-CO-R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(11) $-CO-R_{1\text{-heterocycle}}$ where $R_{1\text{-heterocycle}}$ is as defined above,

(12) $-CO-R_{N-4}$ where R_{N-4} is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1-C_3 alkyl,

(13) $-CO-O-R_{N-5}$ where R_{N-5} is:

(a) C_1-C_6 alkyl, or

(b) $-(CH_2)_{0-2}-(R_{1\text{-aryl}})$ where $R_{1\text{-aryl}}$ is as defined above,

(14) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(15) $-SO-(C_1-C_8$ alkyl),

(16) $-SO_2-(C_3-C_{12}$ alkyl),

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(17) -NH-CO-O-R_{N-5} where R_{N-5} is as defined above,

(18) -NH-CO-N(C_1-C_3 alkyl)$_2$,

(19) -N-CS-N(C_1-C_3 alkyl)$_2$,

(20) -N(C_1-C_3 alkyl)-CO-R_{N-5} where R_{N-5} is as defined above,

(21) -$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,

(22) -R_{N-4} where R_{N-4} is as defined above,

(23) -O-CO-(C_1-C_6 alkyl),

(24) -O-CO-N(C_1-C_3 alkyl)$_2$,

(25) -O-CS-N(C_1-C_3 alkyl)$_2$,

(26) -O-(C_1-C_6 alkyl),

(27) -O-(C_2-C_5 alkyl)-COOH,

(28) -S-(C_1-C_6 alkyl),

(29) C_1-C_6 alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F,

(30) -O-(C_1-C_6 alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F, or

(31) -O-ϕ,

(B) -$R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is:

(A) pyridinyl,

(B) pyrimidinyl,

(C) quinolinyl,

(D) indenyl,

(E) indanyl,

(F) benzothiophenyl,

(G) indolyl,

(H) indolinyl,

(I) pyridazinyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(J) pyrazinyl,

(K) isoindolyl,

(L) isoquinolyl,

(M) quinazolinyl,

(N) quinoxalinyl,

(O) phthalazinyl,

(P) imidazolyl,

(Q) isoxazolyl,

(R) pyrazolyl,

(S) oxazolyl,

(T) thiazolyl,

(U) indolizinyl,

(V) indazolyl,

(W) benzothiazolyl,

(X) benzimidazolyl,

(Y) benzofuranyl,

(Z) furanyl,

(AA) thienyl,

(BB) pyrrolyl,

(CC) oxadiazolyl,

(DD) thiadiazolyl,

(EE) triazolyl,

(FF) tetrazolyl,

(GG) 1, 4-benzodioxan

(HH) purinyl,

(II) oxazolopyridinyl,

(JJ) imidazopyridinyl,

(KK) isothiazolyl,

(LL) naphthyridinyl,

(MM) cinnolinyl,

(NN) carbazolyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(OO) β-carbolinyl,

(PP) isochromanyl,

(QQ) chromanyl,

(RR) furazanyl,

(SS) tetrahydroisoquinoline,

(TT) isoindolinyl,

(UU) isobenzotetrahydrofuranyl,

(VV) isobenzotetrahydrothienyl,

(WW) isobenzothiophenyl,

(XX) benzoxazolyl, or

(YY) pyridopyridinyl,

where the $R_{N\text{-heteroaryl}}$ group is bonded by any atom of the parent $R_{N\text{-heteroaryl}}$ group substituted by hydrogen such that the new bond to the $R_{N\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heteroaryl is unsubstituted or substituted with one or two:

(1) C_1-C_6 alkyl,

(2) -F, -Cl, -Br, or - I,

(3) -OH,

(4) $-NO_2$,

(5) -CO-OH,

(6) $-C\equiv N$,

(7) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are:

(a) -H,

(b) -C_1-C_6 alkyl unsubstituted or substituted with one

(i) -OH, or

(ii) $-NH_2$,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(c) -C_1-C_6 alkyl unsubstituted or substituted with 1, 2, or 3 -F, -Cl, -Br, or -I,

(d) -C_3-C_7 cycloalkyl,

(e -(C_1-C_2 alkyl)-(C_3-C_7 cycloalkyl),

(f) -(C_1-C_6 alkyl)-O-(C_1-C_3 alkyl),

(g) -C_1-C_6 alkenyl with one or two double bonds,

(h) -C_1-C_6 alkynyl with one or two triple bonds,

(i) -C_1-C_6 alkyl chain with one double bond and one triple bond,

(j) -$R_{1\text{-aryl}}$ where $R_{1\text{-aryl}}$ is as defined above, or

(k) -$R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(8) -CO-(C_3-C_{12} alkyl),

(9) -CO-(C_3-C_6 cycloalkyl),

(10) -CO-$R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(11) -CO-$R_{1\text{-heterocycle}}$ where $R_{1\text{-heterocycle}}$ is as defined above,

(12) -CO-$R_{N\text{-}4}$ where $R_{N\text{-}4}$ is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1-C_3 alkyl,

(13) -CO-O-$R_{N\text{-}5}$ where $R_{N\text{-}5}$ is:

(a) C_1-C_6 alkyl, or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(b) $-(CH_2)_{0-2}-(R_{1\text{-aryl}})$ where $R_{1\text{-aryl}}$ is as defined above,

(14) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(15) $-SO-(C_1-C_8$ alkyl),

(16) $-SO_2-(C_3-C_{12}$ alkyl),

(17) $-NH-CO-O-R_{N-5}$ where R_{N-5} is as defined above,

(18) $-NH-CO-N(C_1-C_3$ alkyl$)_2$,

(19) $-N-CS-N(C_1-C_3$ alkyl$)_2$,

(20) $-N(C_1-C_3$ alkyl$)-CO-R_{N-5}$ where R_{N-5} is as defined above,

(21) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,

(22) $-R_{N-4}$ where R_{N-4} is as defined above,

(23) $-O-CO-(C_1-C_6$ alkyl),

(24) $-O-CO-N(C_1-C_3$ alkyl$)_2$,

(25) $-O-CS-N(C_1-C_3$ alkyl$)_2$,

(26) $-O-(C_1-C_6$ alkyl),

(27) $-O-(C_2-C_5$ alkyl$)-COOH$, or

(28) $-S-(C_1-C_6$ alkyl),

(C) $-R_{N\text{-aryl}}-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ is as defined above,

(D) $-R_{N\text{-aryl}}-R_{N\text{-heteroaryl}}$ where $-R_{N\text{-aryl}}$ and $-R_{N\text{-heteroaryl}}$ are as defined above,

(E) $-R_{N\text{-heteroaryl}}-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ and $-R_{N\text{-heteroaryl}}$ are as defined above,

(F) $-R_{N\text{-heteroaryl}}-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(G) $-R_{N\text{-aryl}}-O-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ is as defined above,

(H) $-R_{N\text{-aryl}}-S-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ is as defined above,

(I) $-R_{N\text{-heteroaryl}}-O-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(J) $-R_{N\text{-heteroaryl}}-S-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(K) $-R_{N\text{-aryl}}-CO-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ is as defined above,

(L) $-R_{N\text{-aryl}}-CO-R_{N\text{-heteroaryl}}$ where $-R_{N\text{-aryl}}$ and $R_{N\text{-heteroaryl}}$ are as defined above,

(M) $-R_{N\text{-aryl}}-SO_2-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ is as defined above,

(N) $-R_{N\text{-heteroaryl}}-CO-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(O) $-R_{N\text{-heteroaryl}}-SO_2-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(P) $-R_{N\text{-aryl}}-O-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-aryl}}$ is as defined above,

(Q) $-R_{N\text{-aryl}}-S-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-aryl}}$ is as defined above,

(R) $-R_{N\text{-heteroaryl}}-O-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-heteroaryl}}$ is as defined above, or

(S) $-R_{N\text{-heteroaryl}}-S-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(II) $A-X_N-$ where X_N is $-CO-$,

wherein A is

(A) $-T-E-(Q)_{m'}$,

(1) where -T is

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001



where

(a) x =1 when y = 1 and x = 2 when y = 0,

(b) m is 0, 1, 2 or 3,

(c) the values of x and y vary independently on each carbon when m is 2 and 3, and

(d) R''' varies independently on each carbon and is H, (C_1-C_2) alkyl, phenyl, or phenyl(C_1-C_3)alkyl;

(2) -E is

(a) C_1-C_5 alkyl, but only if m' does not equal 0,

(b) methylthioxy(C_2-C_4)alkyl,

(c) an aryl group having 5 to 7 atoms when monocyclic or having 8 to 12 atoms when fused,

(d) a heterocyclic group having 5 to 7 atoms when monocyclic or having 8 to 12 atoms when fused,

(e) a mono or fused ring cycloalkyl group having 5 to 10 carbon atoms,

(f) biphenyl,

(g) diphenyl ether,

(h) diphenylketone,

(i) phenyl(C_1-C_8)alkyloxyphenyl, or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(j) C_1-C_6 alkoxy;

(3) -Q is

(a) C_1-C_3 alkyl,

(b) C_1-C_3 alkoxy,

(c) C_1-C_3 alkylthioxy,

(d) C_1-C_6 alkylacylamino,

(e) C_1-C_6 alkylacyloxy,

(f) amido (including primary, C_1-C_6 alkyl and phenyl secondary and tertiary amino moieties),

(g) C_1-C_6 alkylamino

(h) phenylamino,

(i) carbamyl (including C_1-C_6 alkyl and phenyl amides and esters),

(j) carboxyl (including C_1-C_6 alkyl and phenyl esters),

(k) carboxy(C_2-C_5)alkoxy,

(l) carboxy(C_2-C5)alkylthioxy,

(m) heterocyclylacyl,

(n) heteroarylacyl, or

(o) hydroxyl;

(4) m' is 0, 1, 2 or 3;

(B) $-E(Q)_{m''}$ wherein E and -Q are as defined as above and m" is 0, 1, 2, or 3;

(C) -T-E wherein -E and -Q are as defined as above; or

(D) -E wherein -E is as defined as above;

(III) -CO-(C_1-C_6 alkyl) where alkyl is unsubstituted or substituted with one or two:

(A) -OH,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(B) $-C_1-C_6$ alkoxy,

(C) $-C_1-C_6$ thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is $-H$, C_1-C_6 alkyl or $-\phi$,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) $-SO_2-(C_1-C_8$ alkyl),

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl),

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl),

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} is the same or different and are as defined above, or

(O) $-O-(C_1-C_5$ alkyl)$-COOH$,

(IV) $-CO-(C_1-C_3$ alkyl$)-O-(C_1-C_3$ alkyl) where alkyl is unsubstituted or substituted with one or two

(A) $-OH$,

(B) $-C_1-C_6$ alkoxy,

(C) $-C_1-C_6$ thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is $-H$, C_1-C_6 alkyl or $-\phi$,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) $-SO_2-(C_1-C_8$ alkyl),

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl),

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl),

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} are the same or different and are as defined above, or

(O) $-O-(C_1-C_5$ alkyl)$-COOH$,

(V) $-CO-(C_1-C_3$ alkyl$)-S-(C_1-C_3$ alkyl) where alkyl is unsubstituted or substituted with one or two

(A) $-OH$,

(B) $-C_1-C_6$ alkoxy,

(C) $-C_1-C_6$ thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is $-H$, C_1-C_6 alkyl or $-\phi$,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) $-SO_2-(C_1-C_8$ alkyl),

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl),

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl),

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} are the same or different and are as defined above, or

(O) $-O-(C_1-C_5$ alkyl$)-COOH$,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(VI) $-CO-CH(-(CH_2)_{0-2}-O-R_{N-10})-(CH_2)_{0-2}-R_{N\text{-}aryl}/R_{N\text{-}heteroaryl}$

where $R_{N\text{-}aryl}$ and $R_{N\text{-}heteroaryl}$ are as defined above,

where R_{N-10} is:

(A) -H,

(B) C_1-C_6 alkyl,

(C) C_3-C_7 cycloalkyl,

(D) C_2-C_6 alkenyl with one double bond,

(E) C_2-C_6 alkynyl with one triple bond,

(F) $R_{1\text{-}aryl}$ where $R_{1\text{-}aryl}$ is as defined above, or

(G) $R_{N\text{-}heteroaryl}$ where $R_{N\text{-}heteroaryl}$ is as defined above;

where B is -O-, -NH-, or -N(C_1-C_6 alkyl)-;

where R_C is:

(I) -(C_1-C_{10})alkyl-K_{1-3} in which:

(A) the alkyl chain is unsubstituted or substituted with one -OH,

(B) the alkyl chain is unsubstituted or substituted with one C_1-C_6 alkoxy unsubstituted or substituted with 1-5 -F,

(C) the alkyl chain is unsubstituted or substituted with one -O-ϕ,

(D) the alkyl chain is unsubstituted or substituted with 1-5 -F,

(E) the alkyl chain is unsubstituted or substituted with a combination of up to three atoms of oxygen and sulfur each such atom replacing one carbon,

(F) each K is:

(1) H,

(2) C_1-C_3 alkyl,

(3) C_1-C_3 alkoxy,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(4) C_1-C_3 alkylthioxy,

(5) C_1-C_6 alkylacylamino,

(6) C_1-C_6 alkylacyloxy,

(7) amido

(8) C_1-C_6 alkylamino

(9) phenylamino,

(10) carbamyl

(11) carboxyl

(12) carboxy(C_2-C_5)alkoxy,

(13) carboxy(C_2-C5)alkylthioxy,

(14) heterocyclylacyl,

(15) heteroarylacyl,

(16) amino unsubstituted or substituted with C_1-C_6 alkyl,

(17) hydroxyl, or

(18) carboxyl methyl ester;

(II)-$(CH_2)_{0-3}$-J-[(-$(CH_2)_{0-3}$-K]$_{1-3}$ where K is as defined above and J is:

(A) a 5 to 7 atom monocyclic aryl group,

(B) a 8 to 12 atom multicyclic aryl group,

(C) a 5 to 7 atom heterocyclic group,

(D) a 8 to 12 atom multicyclic heterocyclic group, or

(E) a 5 to 10 atom monocyclic or multicyclic cycloalkyl group;

(III) -$(CH_2)_{0-3}$-(C_3-C_7) cycloalkyl where cycloalkyl can be unsubstituted or substituted with one, two or three

(A) C_1-C_3 alkyl unsubstituted or substituted with 1, 2, 3, or 4 -F,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

-Cl, -Br, or -I,

(B) -CO-OH,

(C) -CO-O-(C_1-C_4 alkyl),

(D) -OH, or

(E) C_1-C_6 alkoxy,

(IV) $-(CH_2)_{2-6}-OH$,

(V) $-(CR_{C-x}R_{C-y})_{0-4}-R_{C-aryl}$ where R_{C-x} and R_{C-y} are -H, C_1-C_4 alkyl and ϕ- and R_{C-aryl} is the same as R_{N-aryl},

(VI) $-(CH_2)_{0-4}-R_{C-heteroaryl}$ where $R_{C-heteroaryl}$ is:

(A) pyridinyl,

(B) pyrimidinyl,

(C) quinolinyl,

(D) indenyl,

(E) indanyl,

(F) benzothiophenyl,

(G) indolyl,

(H) indolinyl,

(I) pyridazinyl,

(J) pyrazinyl,

(K) isoindolyl,

(L) isoquinolyl,

(M) quinazolinyl,

(N) quinoxalinyl,

(O) phthalazinyl,

(P) isoxazolyl,

(Q) pyrazolyl,

(R) indolizinyl,

(S) indazolyl,

(T) benzothiazolyl,

(U) benzimidazolyl,

(V) benzofuranyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(W) furanyl,

(X) thienyl,

(Y) pyrrolyl,

(Z) oxadiazolyl,

(AA) thiadiazolyl,

(BB) triazolyl,

(CC) tetrazolyl,

(DD) 1, 4-benzodioxan

(EE) purinyl,

(FF) oxazolopyridinyl,

(GG) imidazopyridinyl,

(HH) isothiazolyl,

(II) naphthyridinyl,

(JJ) cinnolinyl,

(KK) carbazolyl,

(LL) β-carbolinyl,

(MM) isochromanyl,

(NN) chromanyl,

(OO) furazanyl,

(PP) tetrahydroisoquinoline,

(QQ) isoindolinyl,

(RR) isobenzotetrahydrofuranyl,

(SS) isobenzotetrahydrothienyl,

(TT) isobenzothiophenyl,

(UU) benzoxazolyl, or

(VV) pyridopyridinyl,

(VII) $-(CH_2)_{0-4}-R_{C\text{-}heterocycle}$ where $R_{C\text{-}heterocycle}$ is the same as $R_{1\text{-}heterocycle}$,

(VIII) $-C(R_{C-1})(R_{C-2})-CO-NH-R_{C-3}$ where R_{C-1} and R_{C-2} are the same or different and are:

(A) -H,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(B) $-C_1-C_6$ alkyl,

(C) $-(C_1-C_4$ alkyl$)-R_{C'\text{-aryl}}$ where $R_{C'\text{-aryl}}$ is as defined above for $R_{1\text{-aryl}}$,

(D) $-(C_1-C_4$ alkyl$)-R_{C\text{-heteroaryl}}$ where $R_{C\text{-heteroaryl}}$ is as defined above,

(E) $-(C_1-C_4$ alkyl$)-R_{C\text{-heterocycle}}$ where $R_{C\text{-heterocycle}}$ is as defined above,

(F) $-R_{C\text{-heteroaryl}}$ where $R_{C\text{-heteroaryl}}$ is as defined above,

(G) $-R_{C\text{-heterocycle}}$ where $R_{C\text{-heterocycle}}$ is as defined above,

(H) $-(CH_2)_{1-4}-OH$,

(I) $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{1-4}-R_{C'\text{-aryl}}$ where R_{C-4} is -O-, -S-, -NH- or $-NHR_{C-5}-$ where R_{C-5} is C_1-C_6 alkyl, and where $R_{C'\text{-aryl}}$ is as defined above,

(J) $-(CH_2)_{1-4}-R_{C-4}-(CH_2)_{1-4}-R_{C\text{-heteroaryl}}$ where R_{C-4} and $R_{C\text{-heteroaryl}}$ are as defined above, or

(K) $-R_{C'\text{-aryl}}$ where $R_{C'\text{-aryl}}$ is as defined above,

and where R_{C-3} is:

(A) -H,

(B) $-C_1-C_6$ alkyl,

(C) $-R_{C'\text{-aryl}}$ where $R_{C'\text{-aryl}}$ is as defined above,

(D) $-R_{C\text{-heteroaryl}}$ where $R_{C\text{-heteroaryl}}$ is as defined above,

(E) $-R_{C\text{-heterocycle}}$ where $R_{C\text{-heterocycle}}$ is as defined above,

(F) $-(C_1-C_4$ alkyl$)-R_{C'\text{-aryl}}$ where $R_{C'\text{-aryl}}$ is as defined above,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

(G) $-(C_1-C_4$ alkyl$)-R_{C\text{-}heteroaryl}$ where $R_{C\text{-}heteroaryl}$ is as defined above, or

(H) $-(C_1-C_4$ alkyl$)-R_{C\text{-}heterocycle}$ where $R_{C\text{-}heterocycle}$ is as defined above,

(IX) $-CH(\phi)_2$,

(X) -cyclopentyl or -cyclohexyl ring fused to a phenyl or heteroaryl ring where heteroaryl is as defined above and phenyl and heteroaryl are unsubstituted or substituted with one, two or three:

(A) C_1-C_3 alkyl,

(B) $-CF_3$,

(C) -F, Cl, -Br and -I,

(D) C_1-C_3 alkoxy,

(E) $-OCF_3$,

(F) $-NH_2$,

(G) -OH, or

(H) $-C\equiv N$,

(XI) $-CH_2-C\equiv CH$;

(XII) $-(CH_2)_{0-1}-CHR_{C-5}-(CH_2)_{0-1}-\phi$ where R_{C-5} is:

(A) -OH, or

(B) $-CH_2-OH$;

(XIII) $-CH(-\phi)-CO-O(C_1-C_3$ alkyl$)$;

(XIV) $-CH(-CH_2-OH)-CH(-OH)-\phi-NO_2$;

(XV) $-(CH_2)_2-O-(CH_2)_2-OH$;

(XVI) $-CH_2-NH-CH_2-CH(-O-CH_2-CH_3)_2$;

(XVII) $-(C_2-C_8)$ alkynyl; or

(XVIII) -H; or a pharmaceutically acceptable salt thereof.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

101. (New) The method of claim 100, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 0.1nM to about 200μM.

102. (New) The method of claim 101, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 10nM to about 100μM.

103. (New) The method of claim 101, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 100nM to about 50μM.

104. (New) The method of claim 103, wherein said compound inhibits 50% of the enzyme's activity at a concentration of from about 1μM to about 10μM.

105. (New) The method of claim 100, wherein said therapeutic amount is in the range of from about 0.1 to about 1000 mg/day.

106. (New) The method of claim 100, wherein said therapeutic amount is in the range of from about 15 to about 1500 mg/day.

107. (New) The method of claim 106, wherein said therapeutic amount is in the range of from about 1 to about 100 mg/day.

108. (New) The method of claim 107, wherein said therapeutic amount is in the range of from about 5 to about 50 mg/day.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

109. (New) The method according to claim 100, wherein the compound is

N-[(1*S*, 2*S*, 4*R*)-1-(3,5-Difluorobenzyl)-4-(*syn*, *syn*)-(3,5 dimethoxycyclohexylcarbamoyl)-2-hydroxyhexyl]-*N*,*N*-dipropylisophathalamide,

6-[6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoylbenzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxyhexanoylamino]-hexanoic acid,

5-[6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoylbenzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxyhexanoylamino]-pentanoic acid,

4-[6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoylbenzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxyhexanoylamino]-butyric acid,

3-[6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoylbenzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxyhexanoylamino]-propionic acid,

8-[6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoylbenzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxyhexanoylamino]-octanoic acid,

8-[6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxy-hexanoylamino]-octanoic acid methyl ester,

N-[4-(*R*)-Butylcarbamoyl-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(R)-isobutylcarbamoyl-hexyl]-*N*,*N*-dipropyl-isophthalamide,

N-[4-(*R*)-Benzylcarbamoyl-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide,

N-[4-(*R*)-(Cyclohexylmethyl-carbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-(piperidine-1-carbonyl)-hexyl]-*N*,*N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-4-(*R*)-(2-dimethylamino-ethylcarbamoyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide,

N-[4-(*R*)-(Butyl-methyl-carbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-(3-hydroxy-propylcarbamoyl)-hexyl]-*N*,*N*-dipropyl-isophthalamide,

4-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid methyl ester,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-4-(*R*)-(3-dimethylamino-propylcarbamoyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide,

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid,

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-2-(*R*)-methyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid,

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-2-(*R*)-propyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid,

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxyl-2-(*R*)-isobutyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid,

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

4-(*anti*)-([2-(*R*)-Benzyl-6-(3,5-difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid,

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-5-methyl-benzoylamino)-2-(*R*)-ethyl-4-(S)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid,

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-5-methyl-benzoylamino)-2-(*R*)-ethyl-4-(S)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid methyl ester,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-(2-morpholin-4-yl-ethylcarbamoyl)-pentyl]-5-methyl-*N,N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-isobutylcarbamoyl-pentyl]-5-methyl-*N,N*-dipropyl-isophthalamide,

N-[4-(*R*)-(2-Diethylamino-ethylcarbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-pentyl]-5-methyl-*N,N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pentyl)-5-methyl-*N,N*-dipropyl-isophthalamide,

N-[4-(*R*)-(Adamantan-2-ylcarbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-pentyl]-5-methyl-*N,N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-methyl-5-morpholin-4-yl-5-oxo-pentyl]-5-methyl-*N,N*-dipropyl-isophthalamide,

N-[4-(*R*)-Benzylcarbamoyl-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-pentyl]-5-methyl-*N,N*-dipropyl-isophthalamide,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

N-[1-(*S*)-(3,5-Difluoro-benzyl)-4-(*R*)-(4-fluoro-benzylcarbamoyl)-2-(*S*)-hydroxy-pentyl]-5-methyl-*N*,*N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-phenethylcarbamoyl-pentyl]-5-methyl-*N*,*N*-dipropyl-isophthalamide,

N-[1-(*S*)-(3,5-Difluoro-benzyl)-4-(*R*)-[(furan-2-ylmethyl)-carbamoyl]-2-(S)-hydroxy-pentyl)-5-methyl-*N*,*N*-dipropyl-isophthalamide, or

N-[1-(*S*)-(3,5-Difluoro-benzyl)-2-(*S*)-hydroxy-4-(*R*)-(prop-2-ynylcarbamoyl)-pentyl]-5-methy-*N*,*N*-dipropyl-isophthalamide.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001